Stay updated on Sepofarsen Safety in Children Clinical Trial
Sign up to get notified when there's something new on the Sepofarsen Safety in Children Clinical Trial page.

Latest updates to the Sepofarsen Safety in Children Clinical Trial page
- Check4 days agoChange DetectedThe study details, eligibility criteria, recruiting locations, and outcome measures appear unchanged.SummaryDifference0.1%

- Check11 days agoChange DetectedThe BRIGHTEN study record for sepofarsen in children with LCA10 is displayed, including its study plan, eligibility requirements, outcome measures, and contact and location details.SummaryDifference68%

- Check18 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check25 days agoChange DetectedAn NIH-wide banner announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the study page’s 403 error.SummaryDifference1%

- Check32 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Sepofarsen Safety in Children Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sepofarsen Safety in Children Clinical Trial page.